References 

1. Asthma GIf. Global strategy for the diagnosis and prevention. Global Initiative for Asthma (updated 2018) 2018. Last accessed March.
2. Ray A, Raundhal M, Oriss TB, Ray P, Wenzel SE. Current concepts of severe asthma. J Clin Invest. 2016;126(7):2394-403.
3. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017;377(10):965-76.
4. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307(6910):982-6.
5. Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol. 2005;115(1):132-8.
6. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. Journal of Clinical Microbiology. 1998;36(2):539-42.
7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-8.
8. Contoli M, Message SD, Laza Stanca V, Edwards MR, Wark PAB, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nature Medicine. 2006;12(9):1023-6.
9. Hewson CA, Jardine A, Edwards MR, Laza Stanca V, Johnston SL. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. Journal of Virology. 2005;79(19):12273-9.
10. Lambrecht BN, Hammad H. The immunology of asthma. Nature Immunology. 2015;16(1):45-56.
11. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(8):3730-4.
12. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Internal Medicine. 1997;36(3):179-85.
13. Ramirez Icaza G, Mohammed KA, Nasreen N, Van Horn RD, Hardwick JA, Sanders KL, et al. Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells. Journal of Clinical Immunology. 2004;24(4):426-34.
14. Bossé Y, Thompson C, Audette K, Stankova J, Rola Pleszczynski M. Interleukin-4 and interleukin-13 enhance human bronchial smooth muscle cell proliferation. International Archives of Allergy and Immunology. 2008;146(2):138-48.
15. Kubota T, Inoue M, Kubota N, Takamoto I, Mineyama T, Iwayama K, et al. Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity. Nature Communications. 2018;9(1):4863-.
16. Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, Lukacs NW. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. European Journal of Immunology. 2002;32(11):3276-84.
17. Hirst SJ, Hallsworth MP, Peng QI, Lee TH. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain. American Journal of Respiratory Critical Care Medicine. 2002;165(8):1161-71.
18. Bischoff SC, Krieger M, Brunner T, Rot A, Von Tscharner V, Baggiolini M, et al. RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. European Journal of Immunology. 1993;23(3):761-7.
19. Prieto J, Lensmar C, Roquet A, van der Ploeg I, Gigliotti D, Eklund A, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respiratory medicine. 2000;94(8):806-14.
20. Chihara J, Yasuba H, Tsuda A, Urayama O, Saito N, Honda K, et al. Elevation of the plasma level of RANTES during asthma attacks. Journal of allergy and clinical immunology. 1997;100(6_Part_2):S52-S5.
21. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England Journal of Medicine. 2010;363(12):1117-27.
22. Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian J-J, Cervantes F, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology Oncology. 2017;10(1):156-.
23. Sha Q, Truong Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. American Journal of Respiratory Cell Molecular Biology. 2004;31(3):358-64.
24. Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumor Biology. 2016;37(11):14701-9.
25. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937-47.
26. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014;190(12):1373-82.
27. Zhu J, Message SD, Qiu Y, Mallia P, Kebadze T, Contoli M, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest. 2014;145(6):1219-29.
28. Message SD, Laza Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(36):13562-7.
29. Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med. 2008;177(10):1082-9.
30. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028-36.e13.
31. Arruda E, Pitkäranta A, Witek TJ, Doyle CA, Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. Journal of Clinical Microbiology. 1997;35(11):2864-8.
32. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. The New England Journal of Medicine. 2010;363(13):1211-21.
33. Venge J, Lampinen M, Håkansson L, Rak S, Venge P. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. Journal of allergy and clinical immunology. 1996;97(5):1110-5.
34. Erin EM, Jenkins GR, Kon OM, Zacharasiewicz AS, Nicholson GC, Neighbour H, et al. Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. American Journal of Respiratory & Critical Care Medicine. 2008;177(2):132-41.
35. Humbert M, Ying S, Corrigan C, Menz G, Barkans J, Pfister R, et al. Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. American Journal of Respiratory Cell & Molecular Biology. 1997;16(1):1-8.
36. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schröder JM. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. The journal of immunology. 1996;157(4):1806-12.
37. Tonnel AB, Gosset P, Tillie Leblond I. Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus. International Archives of Allergy and Immunology. 2001;124(1-3):267-71.
38. Culley FJ, Pennycook AMJ, Tregoning JS, Dodd JS, Walzl G, Wells TN, et al. Role of CCL5 (RANTES) in viral lung disease. Journal of Virology. 2006;80(16):8151-7.
39. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nature Reviews Immunology. 2014;14(5):315-28.
40. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817-30.
41. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annual Review of Immunology. 2014;32:513-45.
42. Øvrevik J, Låg M, Lecureur V, Gilot D, Lagadic Gossmann D, Refsnes M, et al. AhR and Arnt differentially regulate NF-κB signaling and chemokine responses in human bronchial epithelial cells. Cell Communication and Signaling. 2014;12:48-.
43. Matsukura S, Kokubu F, Kurokawa M, Kawaguchi M, Ieki K, Kuga H, et al. Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clinical Experimental Allergy. 2006;36(8):1049-62.
44. Lam K-P, Chu Y-T, Kuo C-H, Wang W-L, Tok T-S, Chin Y-Y, et al. Suppressive effects of procaterol on expression of IP-10/CXCL 10 and RANTES/CCL 5 by bronchial epithelial cells. Inflammation. 2011;34(4):238-46.
45. Eidet JR, Reppe S, Pasovic L, Olstad OK, Lyberg T, Khan AZ, et al. The Silk-protein Sericin Induces Rapid Melanization of Cultured Primary Human Retinal Pigment Epithelial Cells by Activating the NF-κB Pathway. Scientific Reports. 2016;6:22671-.
46. Perng Y-C, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nature Reviews Microbiology. 2018;16(7):423-39.
47. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nature Reviews Immunology. 2014;14(1):36-49.
48. Joshi S, Kaur S, Kroczynska B, Platanias LC. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine (Philadelphia, Pa Print). 2010;52(1-2):123-7.
49. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, et al. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. Journal of Biological Chemistry. 1997;272(39):24183-90.
50. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (Philadelphia, Pa Print). 2015;75(1):38-50.
51. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. The journal of immunology. 2012;189(9):4213-9.
52. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut. 2012;61(12):1765-73.
53. Bartolomé RA, García Palmero I, Torres S, López Lucendo M, Balyasnikova IV, Casal JI. IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Research. 2015;75(12):2434-44.
54. Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nature Structural and Molecular Biology. 2004;11(11):1060-7.
55. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. Journal of Cell Science. 2004;117(Part_8):1281-3.